Global pharma giant Eli Lilly is committing $1 billion to establish a contract manufacturing and oversight facility in Hyderabad, reinforcing the city’s status as a life sciences hub.
Glimpse:
Eli Lilly’s new investment will focus on contract manufacturing, quality oversight, and expansion of global production capabilities in Hyderabad. This marks a major boost to Telangana’s pharma ecosystem and signals rising confidence in local R&D and manufacturing infrastructure.
In a landmark move, Eli Lilly has announced a $1 billion investment in a new contract manufacturing and oversight facility in Hyderabad. The plant is aimed at enhancing India’s global pharmaceutical supply chain and strengthening quality control practices.
This follows the company’s earlier establishment of a Global Capability Center in Hyderabad. State officials highlighted the investment as one of the largest in recent years for Telangana’s life sciences sector. The facility is expected to generate numerous jobs in manufacturing, analytics, and regulatory compliance.
Officials from both the company and the state government signed agreements outlining support measures from land and infrastructure incentives to streamlined regulatory facilitation. The investment underscores Hyderabad’s emergence as a premier center for pharma innovation and production in Asia.
“Hyderabad is no longer just a participant it’s ascending as a global node in pharma manufacturing.”
By
HB Team
